666 episodes
ReachMD CME ReachMD
-
- Science
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
-
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-biomarkers-of-response-to-immunotherapeutic-regimens/24356/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care. -
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
CME credits: 1.00
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/evolutions-in-duchenne-muscular-dystrophy-treatment-implications-for-the-present-and-future/20369/
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
= -
Managing Immune-Related Adverse Events With Immunotherapies
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-immune-related-adverse-events-with-immunotherapies/24358/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care. -
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care. -
Overcoming Barriers to Equitable Care in HNSCC
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care. -
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.